Generated by AI
Surrozen, Inc. is a biotechnology company focused on developing antibody-based therapeutics that selectively modulate the Wnt pathway to support tissue repair and regeneration. The company’s current programs are centered on ophthalmology, with candidates aimed at retinal diseases, diabetic macular edema, wet age-related macular degeneration, uveitic macular edema, Fuchs’ endothelial corneal dystrophy, and geographic atrophy. Surrozen also works on tissue-specific biologics designed to engage the body’s natural repair mechanisms in other disease areas, including the intestine, liver, lung, kidney, skin, pancreas, and central nervous system. Based in South San Francisco, California, Surrozen’s role in the market is that of a clinical-stage drug developer pursuing precision biologics for serious conditions with high unmet medical need.
Website171 Oyster Point Boulevard
South San Francisco, CA, 94080
United States
The latest articles about SRZN.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology comp...
Summary of Oct 2's posts. Generated by AI.
Summary of Sep 24's posts. Generated by AI.
Summary of Feb 13's posts. Generated by AI.
Summary of Sep 25's posts. Generated by AI.
Investors talking about SRZN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.